Dana consortium on HIV dementia begins with study of Otsuka's OPC-14117.
Executive Summary
DANA HIV DEMENTIA CONSORTIUM STUDYING OTSUKA's OPC-14117 in the first trial to be undertaken by the Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. The initial trial uses Otsuka Pharmaceutical's OPC-14117 under an IND held by investigator Karl Kieburtz, MD, University of Rochester. Otsuka is donating drug and placebo and allowed cross referencing of its DMF and IND; the agreement is not licensure and Otsuka retains rights to further development.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth